Recent Updates
Recently added Catalysts
CYTK Negative Sentiment Score: 30/100

Cytokinetics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuits Against Cytokinetics, Incorporated - CYTK

Key Takeaway: Cytokinetics, Incorporated is currently involved in a securities class action lawsuit due to allegations of failing to disclose critical information during a designated class period. Investors have until November 17, 2025, to file lead plaintiff applications in this case, which is pending in the Northern District of California. The company's share price experienced a notable decline following FDA's decisions related to its aficamten product. This situation may impact the company's reputation and investor confidence moving forward.

Market Sentiment Analysis

CONCERNS & RISKS

  • Cytokinetics is facing a securities class action lawsuit due to alleged failure to disclose material information.
  • The company's share price fell significantly after FDA decisions regarding its New Drug Application for aficamten.
  • Investors with losses exceeding $100,000 are reminded of the upcoming lead plaintiff application deadline.

Full Press Release Details

NEW ORLEANS, Oct. 22, 2025 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until November 17, 2025 to file lead plaintiff applications in a securities class action lawsuit against Cytokinetics, Incorporated (NasdaqGS: CYTK), if they purchased or otherwise acquired the Company’s securities between December 27, 2023 and May 6, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of California.
Cytokinetics investors should visit us at https://www.claimsfiler.com/cases/nasdaq-cytk or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.
Cytokinetics and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On March 10, 2025, the Company disclosed that the U.S. Food and Drug Administration (“FDA”) had decided not to convene an advisory committee meeting to review the Company’s New Drug Application (“NDA”) for its aficamten product. Then, on May 6, 2025, the Company disclosed that it had held multiple pre-NDA meetings with the FDA discussing safety monitoring and risk mitigation but chose to submit the NDA without a Risk Evaluation and Mitigation Strategy, instead relying on labeling and voluntary education materials.
On this news, the price of Cytokinetics’ shares fell, closing at $33.04 per share on May 7, 2025.
The case is Seidman v. Cytokinetics, Incorporated, et al., No. 25-cv-07923.
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.
To learn more about ClaimsFiler, visit www.claimsfiler.com.

Tags

Securities Litigation

Frequently Asked Questions

What is the deadline for filing claims against Cytokinetics?

The deadline to file lead plaintiff applications is November 17, 2025.

What was disclosed by Cytokinetics on March 10, 2025?

Cytokinetics announced that the FDA would not hold a meeting on its NDA for aficamten.

What can investors do at ClaimsFiler.com?

Investors can register, upload data for notifications, and inquire about legal evaluations.

What caused Cytokinetics' share price to fall?

The company's announcements regarding their NDA led to a share price drop on May 7, 2025.

Who handles the legal aspects of the securities lawsuit?

Lawyers from Kahn Swick & Foti, LLC manage the legal options for investors.

Last updated: Oct 23, 2025